Accumulation of hydroxyethyl starch (HES) in the liver of patients with renal failure and portal hypertension.
Hydroxyethyl starch (HES) has gained wide clinical acceptance as a colloidal plasma substitute. We were able to study the liver biopsies of two patients with renal failure who developed ascites after repeated infusions of HES. All types of liver cells displayed massive accumulation of HES with the morphologic resemblance to a storage disease. These changes could be distinguished clearly from the lesions of a hereditary disorder by light and electron microscopy. Although it is difficult to establish a causative role for HES in the development of ascites on the bases of morphological changes alone, one should be cautious about giving HES to patients with renal failure until exact data from further experimental studies are available.
D005260:Female; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000009:adverse effects* / Q000378:metabolism; D006975:Hypertension, Portal / Q000139:chemically induced*; D007022:Hypotension / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy*; D008099:Liver / Q000378:metabolism* / Q000473:pathology / Q000648:ultrastructure; D008297:Male; D008854:Microscopy, Electron; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects; D013213:Starch / Q000031:analogs & derivatives*
D006895:Hydroxyethyl Starch Derivatives; D013213:Starch